BED-based cross-radionuclide estimation of alpha-PSMA dosing from 177 Lu-PSMA dosimetry (EANM 2026) - Sep 29, 2026 - Abstract #EP-1038; "Aim/Introduction: To estimate dosing for 225Ac-, 212Pband 211At-labeled PSMA radioligands from published 177Lu-PSMA-617 dosimetry data using a biologically effective dose (BED) and physics scaling based model... Estimated dose coefficients for bone metastases were 1609 mGy/MBq for 225Ac-PSMA, 93.5 mGy/MBq for 212Pb-PSMA and 146 mGy/MBq for 211At-PSMA, compared with 3.60 mGy/MBq for 177Lu-PSMA... BED-based half-life-adjusted scaling of published 177Lu-PSMA dosimetry can provide practical starting estimates for alpha-emitting PSMA regimens. The approach also preserves explicit linkage between published 177Lu benchmarks and proposed alpha-emitter activity ranges, which may facilitate transparent discussion with regulators and trial teams. The model identifies marrow BED as the principal activity constraint and supports comparative evaluation of candidate radionuclides for early clinical development."
First-in-human • Solid Tumor
|